Neuroendocrine tumours: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R43

  Development of a PET Imaging Platform to De-Risk AAV Gene Therapy Clinical Trials

  Neocell Technologies Inc· Fair Lawn, United States· US$306,395 awarded in fiscal year 2026· until Sept 2027

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, United States· US$1,174,824 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Novel Non-Mutagenic Ribosome Biogenesis Inhibitors for the Treatment of Small Cell Lung Cancer

  Palade Therapeutics Inc.· Austin, United States· US$404,087 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  High-Performance Next-Generation SPECT-CT (NxSPECT) for Theranostics

  Yale University· New Haven, United States· US$532,637 awarded in fiscal year 2026· until Aug 2031

• NIH NIBIB · U24

  Medical Imaging and Data Resource Center (MIDRC) – Expansion to Theranostics

  University of Chicago· Chicago, United States· US$1,014,676 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €268,569· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €4,574,378· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norway· EU contribution €4,773,849· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxembourg· EU contribution €14,837,694· until Dec 2029· 13 countries

10 of 194 running projects, newest first. Listed amounts together: US$116.1m + €37.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 186
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 202
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Single-cell transcriptomics reveals transcriptional reprogramming and microenvironmental remodeling in ectopic ACTH/CRH-secreting pheochromocytomas.

  J Transl Med, Oct 2026

• Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.

  Exp Dermatol, Oct 2026

• Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance.

  Cell Rep Med, Sept 2026

• Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.

  Cell Rep Med, Sept 2026

• Predicting Targeted and Immunotherapeutic Response Outcomes in Melanoma With Single-Cell Raman Spectroscopy and Artificial Intelligence.

  JCO Precis Oncol, Sept 2026

• Spatially-resolved single-cell imaging of melanoma brain metastases identifies localized immune patterns predictive of immune checkpoint blockade response.

  Neuro Oncol, Sept 2026

• Single-cell profiling reveals an XBP1s-associated ER proteostasis state linked to metastatic stress adaptation in melanoma.

  Cell Signal, Aug 2026

• scE2TM improves single-cell embedding interpretability and reveals cellular perturbation signatures.

  Nat Commun, Aug 2026

• Dissecting the interplay between dedicator of cytokinesis 2 and neutrophil extracellular traps in sculpting the immune landscape and clinical outcome of melanoma using a single-cell atlas.

  Melanoma Res, Aug 2026

• Single-cell multimodal profiling of pan-cancer cell lines uncovers gene regulatory principles underlying intrinsic cell states and environmental features.

  Nat Commun, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.